All Pathways
GastroenterologyEmergency

IBD Acute Severe Flare Management (ACG 2020)

IBD Acute Severe Flare Management (ACG 2020): Acute Severe IBD Flare → Assess Severity (Truelove-Witts) → Initial Workup → Complications Present? → ⚠️ S...

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Acute Severe IBD Flare

    Known IBD with severe symptoms requiring hospitalization

    1. Action

      Assess Severity (Truelove-Witts)

      For UC - defines acute severe colitis

      • ≥6 bloody stools/day PLUS ≥1 of:
      • • HR >90 bpm
      • • Temp >37.8°C
      • • Hgb <10.5 g/dL
      • • ESR >30 mm/hr
      • Crohn's: use CDAI or Harvey-Bradshaw
      1. Action

        Initial Workup

        Rule out complications and infections

        • Stool C. diff, culture, ova & parasites
        • CMV PCR or tissue (if on immunosuppression)
        • CBC, CMP, CRP, ESR, albumin
        • AXR or CT if concern for toxic megacolon
        • Flexible sigmoidoscopy (limited, avoid perforation)
        1. Decision

          Complications Present?

          Toxic megacolon, perforation, obstruction, abscess

          1. Warning

            ⚠️ Surgical Consult

            Immediate surgical evaluation needed

            • Toxic megacolon (colon >6cm)
            • Perforation/peritonitis
            • Uncontrolled hemorrhage
            • Abscess (Crohn's) - may need IR drainage
            1. Warning

              Colectomy

              Subtotal colectomy with end ileostomy

              • For UC: curative option
              • Later IPAA (J-pouch) consideration
              • Better outcomes with planned surgery vs. emergency
          2. Action

            IV Corticosteroids

            First-line for acute severe UC/Crohn's flare

            • Methylprednisolone 60mg IV daily
            • OR Hydrocortisone 100mg IV q8h
            • NPO or clear liquids initially
            • VTE prophylaxis (LMWH)
            • Avoid antidiarrheals/opioids
            1. Action

              Supportive Care

              Concurrent management

              • IV fluids, correct electrolytes
              • Transfuse if Hgb <7-8
              • Nutrition (enteral > TPN if possible)
              • VTE prophylaxis essential
              • Daily clinical and AXR assessment
              1. Decision

                Day 3 Assessment

                Evaluate response to IV steroids

                • Oxford criteria: stool frequency + CRP
                • >8 stools/day OR 3-8 stools + CRP >45 = likely steroid failure
                1. Action

                  Steroid Response

                  Improving by day 3-5

                  • Continue IV steroids until stable
                  • Transition to PO prednisone
                  • Start/optimize maintenance therapy
                  • Taper steroids over 6-8 weeks
                  1. Outcome

                    Clinical Remission

                    Optimize maintenance therapy, close outpatient follow-up

                  2. Outcome

                    Maintenance Therapy

                    Infliximab, adalimumab, vedolizumab, ustekinumab, tofacitinib per disease

                2. Warning

                  Steroid-Refractory (No response by day 3-5)

                  Rescue therapy needed

                  • Infliximab 5-10 mg/kg IV (preferred)
                  • OR Cyclosporine 2-4 mg/kg/day IV
                  • OR Vedolizumab (slower onset)
                  • Check CMV, C. diff again
                  • Continue surgical evaluation
                  1. Decision

                    Response to Rescue Therapy?

                    Assess by day 5-7 of rescue therapy

Guideline Source

ACG Clinical Guidelines: Ulcerative Colitis in Adults (2019) & Crohn's Disease (2018)

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Primarily addresses acute severe UC (Truelove-Witts criteria)
  • Crohn's flares may have different triggers (abscess, stricture)
  • Biologic choice evolving rapidly
  • CMV reactivation testing important in refractory cases
  • Surgical timing requires multidisciplinary input

Applicable Regions

USEUGlobal

EU: ECCO guidelines are similar

US: ACG guidelines current standard

Version 1Next review: 2027-01-01

Frequently Asked Questions

What is the IBD Acute Severe Flare Management (ACG 2020)?

The IBD Acute Severe Flare Management (ACG 2020) is a emergency clinical algorithm for Gastroenterology. It provides a structured decision tree to guide clinical decision-making, based on ACG Clinical Guidelines: Ulcerative Colitis in Adults (2019) & Crohn's Disease (2018).

What guideline is the IBD Acute Severe Flare Management (ACG 2020) based on?

This algorithm is based on ACG Clinical Guidelines: Ulcerative Colitis in Adults (2019) & Crohn's Disease (2018) (DOI: 10.14309/ajg.0000000000000152).

What are the limitations of the IBD Acute Severe Flare Management (ACG 2020)?

Known limitations include: Primarily addresses acute severe UC (Truelove-Witts criteria); Crohn's flares may have different triggers (abscess, stricture); Biologic choice evolving rapidly; CMV reactivation testing important in refractory cases; Surgical timing requires multidisciplinary input. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the IBD Acute Severe Flare Management (ACG 2020) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free